6 documents found, page 1 of 1
Urgent request for pretomanid label expansion to align with WHO guidelines and ...
Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; Cirillo, DM; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, CPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies...
Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in E...
Kirakosyan, O; Reimann, M; Andersen, AB; Bjarnason, A; Bakos, Á; Dyrhol-Riise, AM; McLaughlin, AM; Nita, C; Pieridou, D; Chesov, D; Davidavičienė, EV"Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. Methods: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group ...
Tuberculosis incidence in foreign-born people residing in European countries in...
Vasiliu, A; Köhler, N; Altpeter, E; Ægisdóttir, TR; Amerali, M; de Oñate, WA; Bakos, Á; D'Amato, S; Cirillo, DM; van Crevel, R; Davidaviciene, E"Background European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim We aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening. Methods The Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB...
Rifapentine access in Europe: growing concerns over key tuberculosis treatment ...
Guglielmetti, L; Günther, G; Leu, C; Cirillo, D; Duarte, R; Garcia-Basteiro, AL; Goletti, D; Jankovic, M; Kuksa, L; Maurer, FP; Méchaï, F; Tiberi, S[No abstract available]
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Magis-Escura, C; Günther, G; Lange, C; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Davilovits, M
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
Günther, G; van Leth, F; Altet, N; Dedicoat, M; Duarte, R; Gualano, G; Kunst, H; Muylle, I; Spinu, V; Tiberi, S; Viiklepp, P; Lange, CThe emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone an...